Musings from The Power List: Renee Aguiar-Lucander

Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner

1

Renee Aguiar-Lucander joined Hansa Biopharma as CEO to recapitalize and turn the business around, achieving a significant Phase 3 study result.
2

The Phase 3 study's high statistical significance (p < 0.0001) enabled Hansa to file a Biologics License Application with the FDA.
3

Aguiar-Lucander emphasizes the need for timely clinical trials and improved oversight of contract research organizations.
4

She advocates for reducing regulatory demands for randomized trials in early phases for rare diseases, favoring real-world evidence.
5

Aguiar-Lucander predicts that in 10 years, drug development will see reduced regulatory review times and increased use of AI and real-world evidence.

1